Quick Takeaways
- KROS - Keros Therapeutics, Inc. has 21 insiders with reported activity on this page.
- Net insider value flow over the last year: -$171,479,448.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 21 Insiders of Keros Therapeutics, Inc.
- Symbol
- KROS on Nasdaq
- Location
- Lexington, MA
What Changed
- Buy value: $9,486,932; sell value: $180,966,380.
- Net share flow: <span class="text-red-600">-9,260,709</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$171,479,448.
Buys
$9,486,932
Shares: 936,258
Insiders: 2
Sells
$180,966,381
Shares: 10,196,967
Insiders: 6
Net
-$171,479,448
Shares: -9,260,709
Insiders: -4
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 2,000 | 20,372 | $22,420 | $331,820 | +$354,240 |
| 3-6 | 0 | 10,176,595 | $0 | $180,634,561 | +$180,634,561 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 934,258 | 0 | $9,464,512 | $0 | +$9,464,512 |
Keros Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER, Director | $8,972,814 | -$113,433 | -1.2% | Mixed | 02 Apr 2026 |
| Jennifer Lachey | Chief Scientific Officer | $4,307,079 | Mixed | 15 Jul 2022 | ||
| Christopher Rovaldi | Chief Operating Officer | $2,640,600 | Mixed | 18 Feb 2025 | ||
| Tomer Kariv | Director, 10%+ Owner | $2,241,983 | Mixed | 04 Jun 2025 | ||
| Ran Nussbaum | Director, 10%+ Owner | $2,241,983 | Mixed | 04 Jun 2025 | ||
| Yung H. Chyung | Chief Medical Officer | $1,936,440 | Mixed | 18 Feb 2025 | ||
| Julius Knowles | Director | $1,927,352 | Mixed | 21 Nov 2025 | ||
| ORBIMED ADVISORS LLC | Director | $799,761 | Mixed | 21 Nov 2025 | ||
| Carl L. Gordon | Director | $799,761 | Mixed | 21 Nov 2025 | ||
| Esther Cho | Chief Legal Officer | $649,994 | -$77,581 | -11% | Filing P/S | 24 Feb 2026 |
| Keith Regnante | Chief Financial Officer | $641,917 | -$77,483 | -11% | Filing P/S | 24 Feb 2026 |
| Lorena Raquel Lerner | Chief Scientific Officer | $508,926 | -$63,324 | -11% | Filing P/S | 24 Feb 2026 |
| Charles W. Newton | Director | $227,826 | Mixed | 09 Mar 2026 | ||
| Pontifax Management 4 G.P. (2015) Ltd. | 10%+ Owner | $166,110 | -$84,975,125 | -100% | Mixed | 15 Oct 2025 |
| Jean J. Bienaime | Director | $83,514 | +$22,420 | +37% | Filing P/S | 09 Mar 2026 |
| Alpna Seth | Director | $75,810 | Mixed | 04 Jun 2025 | ||
| Nima Farzan | Director | $75,810 | Mixed | 04 Jun 2025 | ||
| Mary Ann Gray | Director | $75,810 | Mixed | 04 Jun 2025 | ||
| ADAR1 Capital Management, LLC | 10%+ Owner | $0 | -$86,194,924 | -100% | Mixed | 15 Oct 2025 |
| Simon Peter Cooper | Chief Medical Officer | Mixed | 13 Feb 2024 | |||
| Claudia Ordonez | Chief Medical Officer | Mixed | 11 Jun 2021 |
Top shareholders of Keros Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
|
Company |
7.5%
|
2,290,532
|
$46,635,220 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5%
|
1,525,355
|
$31,056,228 | — | 31 Dec 2025 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
4.4%
|
1,334,516
|
$27,170,746 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.5%
|
1,075,993
|
$21,907,217 | — | 31 Dec 2025 | |
| Madison Avenue Partners, LP |
13F
13D/G
|
Company · Madison Avenue International LP |
2.7%
from 13D/G
|
823,707
|
$16,770,675 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
3/4/5
|
Company · Director |
0.15%
from 3/4/5
|
804,212
|
$16,373,756 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
2.6%
|
783,918
|
$15,960,570 | — | 31 Dec 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13D/G
|
— |
2.7%
|
1,101,000
|
$15,645,210 | $0 | 31 Dec 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
2.5%
|
768,425
|
$15,645,133 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2.5%
|
755,473
|
$15,381,430 | — | 31 Dec 2025 | |
| D. E. SHAW & CO, L.P. |
13D/G
|
— |
3.9%
|
756,156
|
$14,745,042 | -$15,400,944 | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
2.1%
|
654,724
|
$13,330,180 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
635,208
|
$12,935,496 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.9%
|
591,686
|
$12,046,727 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.9%
|
590,517
|
$12,022,926 | — | 31 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
1.7%
|
704,472
|
$10,010,547 | $0 | 31 Jan 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.5%
|
472,520
|
$9,620,507 | — | 31 Dec 2025 | |
| Jasbir Seehra |
3/4/5
|
CHIEF EXECUTIVE OFFICER, Director |
—
mixed-class rows
|
638,152
mixed-class rows
|
$8,972,814 | -$113,433 | 02 Apr 2026 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.2%
|
360,419
|
$7,338,131 | — | 31 Dec 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
1.1%
|
321,346
|
$6,542,605 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1%
|
318,439
|
$6,483,418 | — | 31 Dec 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.86%
|
260,891
|
$5,311,000 | — | 31 Dec 2025 | |
| Weiss Asset Management LP |
13F
|
Company |
0.83%
|
254,063
|
$5,172,723 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.82%
|
250,571
|
$5,101,626 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.76%
|
230,492
|
$4,692,833 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.72%
|
220,209
|
$4,483,455 | — | 31 Dec 2025 | |
| Jennifer Lachey |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
103,855
mixed-class rows
|
$4,307,079 | — | 15 Jul 2022 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.64%
|
195,281
|
$3,975,921 | — | 31 Dec 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.63%
|
193,607
|
$3,942,000 | — | 31 Dec 2025 | |
| Man Group plc |
13F
|
Company |
0.62%
|
190,207
|
$3,872,615 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.61%
|
186,779
|
$3,802,820 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.59%
|
180,543
|
$3,675,854 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.56%
|
171,800
|
$3,497,848 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.53%
|
162,009
|
$3,298,504 | — | 31 Dec 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.53%
|
161,136
|
$3,280,729 | — | 31 Dec 2025 | |
| NOMURA HOLDINGS INC |
13F
|
Company |
0.51%
|
156,753
|
$3,191,491 | — | 31 Dec 2025 | |
| BESSEMER GROUP INC |
13F
|
Company |
0.47%
|
143,853
|
$2,929,000 | — | 31 Dec 2025 | |
| Christopher Rovaldi |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
60,000
|
$2,640,600 | — | 18 Feb 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.4%
|
122,828
|
$2,500,778 | — | 31 Dec 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.4%
|
122,821
|
$2,500,636 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.4%
|
121,582
|
$2,475,410 | — | 31 Dec 2025 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.38%
|
117,361
|
$2,389,470 | — | 31 Dec 2025 | |
| PDT Partners, LLC |
13F
|
Company |
0.37%
|
112,183
|
$2,284,046 | — | 31 Dec 2025 | |
| Ran Nussbaum |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
165,762
mixed-class rows
|
$2,241,983 | — | 04 Jun 2025 | |
| Tomer Kariv |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
165,762
mixed-class rows
|
$2,241,983 | — | 04 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.33%
|
100,114
|
$2,038,320 | — | 31 Dec 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
0.32%
|
98,703
|
$2,010,000 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.32%
|
97,084
|
$1,976,631 | — | 31 Dec 2025 | |
| Rangeley Capital, LLC |
13F
|
Company |
0.32%
|
96,800
|
$1,970,848 | — | 31 Dec 2025 | |
| Yung H. Chyung |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
154,000
mixed-class rows
|
$1,936,440 | — | 18 Feb 2025 |
Recent Insider Transactions by Companies or Individuals for Keros Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jasbir Seehra | KROS | Common Stock | Options Exercise | 14.3% | 55,000 | 440,708 | 02 Apr 2026 | Direct | ||
| Jasbir Seehra | KROS | Employee Stock Option (Right to Buy) | Options Exercise | -21.8% | -55,000 | 197,444 | 02 Apr 2026 | Direct | ||
| Charles W. Newton | KROS | Common Stock | Award | 13,215 | 13,215 | 09 Mar 2026 | Direct | |||
| Charles W. Newton | KROS | Stock Option (Right to Buy) | Award | 14,788 | 14,788 | 09 Mar 2026 | Direct | |||
| Jean Jacques Bienaime | KROS | Common Stock | Purchase | 36.7% | $22,420 | $11.21 | 2,000 | 7,450 | 09 Mar 2026 | Direct |
| Esther Cho | KROS | Employee Stock Option (Right to Buy) | Award | 80,000 | 80,000 | 24 Feb 2026 | Direct | |||
| Jasbir Seehra | KROS | Employee Stock Option (Right to Buy) | Award | 317,000 | 217,000 | 24 Feb 2026 | Direct | |||
| Keith Regnante | KROS | Employee Stock Option (Right to Buy) | Award | 60,000 | 60,000 | 24 Feb 2026 | Direct | |||
| Esther Cho | KROS | Employee Stock Option (Right to Buy) | Award | 80,000 | 80,000 | 24 Feb 2026 | Direct | |||
| Lorena Raquel Lerner | KROS | Employee Stock Option (Right to Buy) | Award | 75,000 | 75,000 | 24 Feb 2026 | Direct | |||
| Jasbir Seehra | KROS | Common Stock | Sale | -1.79% | $113,433 | $16.17 | -7,015 | 385,708 | 19 Feb 2026 | Direct |
| Lorena Raquel Lerner | KROS | Common Stock | Sale | -11.1% | $63,324 | $16.35 | -3,873 | 31,127 | 18 Feb 2026 | Direct |
| Esther Cho | KROS | Common Stock | Sale | -10.7% | $77,581 | $16.35 | -4,745 | 39,755 | 18 Feb 2026 | Direct |
| Keith Regnante | KROS | Common Stock | Sale | -10.8% | $77,483 | $16.35 | -4,739 | 39,261 | 18 Feb 2026 | Direct |
| Jasbir Seehra | KROS | Employee Stock Option (right to buy) | Award | 62,500 | 62,500 | 07 Jan 2026 | Direct | |||
| Orbimed Advisors Llc | KROS | Common Stock | Disposed to Issuer | -82.6% | -214,522 | 45,057 | 21 Nov 2025 | See footnotes | ||
| Carl L. Gordon | KROS | Common Stock | Disposed to Issuer | -82.6% | -214,522 | 45,057 | 21 Nov 2025 | See footnotes | ||
| Julius Knowles | KROS | Common Stock | Disposed to Issuer | -75.9% | -322,021 | 102,233 | 21 Nov 2025 | See footnote | ||
| Pontifax Management 4 G.P. (2015) Ltd. | KROS | Common Stock, $0.0001 par value per share | Sale | -100% | $2,755,900 | $17.75 | -155,262 | 0 | 15 Oct 2025 | By Pontifax Late Stage Fund, L.P. |
| Pontifax Management 4 G.P. (2015) Ltd. | KROS | Common Stock, $0.0001 par value per share | Sale | -100% | $21,768,813 | $17.75 | -1,226,412 | 0 | 15 Oct 2025 | By Pontifax (China) IV, L.P. |
| Pontifax Management 4 G.P. (2015) Ltd. | KROS | Common Stock, $0.0001 par value per share | Sale | -100% | $19,898,549 | $17.75 | -1,121,045 | 0 | 15 Oct 2025 | By Pontifax (Cayman) IV, L.P. |
| Pontifax Management 4 G.P. (2015) Ltd. | KROS | Common Stock, $0.0001 par value per share | Sale | -100% | $40,551,863 | $17.75 | -2,284,612 | 0 | 15 Oct 2025 | By Pontifax (Israel) IV, L.P. |
| ADAR1 Capital Management, LLC | KROS | Common Stock | Sale | -100% | $13,194,604 | $17.75 | -743,358 | 0 | 15 Oct 2025 | By Spearhead Insurance Solutions IDF, LLC |
| ADAR1 Capital Management, LLC | KROS | Common Stock | Sale | -100% | $4,520,375 | $17.75 | -254,669 | 0 | 15 Oct 2025 | By ADAR1 SPVI, LP |
| ADAR1 Capital Management, LLC | KROS | Common Stock | Sale | -100% | $77,944,457 | $17.75 | -4,391,237 | 0 | 15 Oct 2025 | By ADAR1 Partners, LP |
| Jasbir Seehra | KROS | Common Stock | Award | 29.9% | 90,500 | 392,723 | 03 Sep 2025 | Direct | ||
| ADAR1 Capital Management, LLC | KROS | Common Stock | Exercise of in-the-money or at-the-money derivative security | -0.03% | -200 | 743,358 | 20 Jun 2025 | By Spearhead Insurance Solutions IDF, LLC | ||
| ADAR1 Capital Management, LLC | KROS | Common Stock | Exercise of in-the-money or at-the-money derivative security | -0.03% | -1,500 | 4,391,237 | 20 Jun 2025 | By ADAR1 Partners, LP | ||
| ADAR1 Capital Management, LLC | KROS | Put Option (right to sell) | Exercise of in-the-money or at-the-money derivative security | -100% | -2 | 0 | 20 Jun 2025 | By Spearhead Insurance Solutions IDF, LLC | ||
| ADAR1 Capital Management, LLC | KROS | Put Option (right to sell) | Exercise of in-the-money or at-the-money derivative security | -100% | -15 | 0 | 20 Jun 2025 | By ADAR1 Partners, LP | ||
| Julius Knowles | KROS | Common Stock | Award | 440.8% | 5,250 | 6,441 | 04 Jun 2025 | Direct | ||
| Julius Knowles | KROS | Stock Option (right to buy) | Award | 10,500 | 10,500 | 04 Jun 2025 | Direct | |||
| Carl L. Gordon | KROS | Common Stock | Award | 5,250 | 5,250 | 04 Jun 2025 | Direct | |||
| Carl L. Gordon | KROS | Stock Option (right to buy) | Award | 10,500 | 10,500 | 04 Jun 2025 | Direct | |||
| Nima Farzan | KROS | Common Stock | Award | 5,250 | 5,250 | 04 Jun 2025 | Direct | |||
| Nima Farzan | KROS | Stock Option (right to buy) | Award | 10,500 | 10,500 | 04 Jun 2025 | Direct | |||
| Alpna Seth | KROS | Common Stock | Award | 5,250 | 5,250 | 04 Jun 2025 | Direct | |||
| Alpna Seth | KROS | Stock Option (right to buy) | Award | 10,500 | 10,500 | 04 Jun 2025 | Direct | |||
| Mary Ann Gray | KROS | Common Stock | Award | 5,250 | 5,250 | 04 Jun 2025 | Direct | |||
| Mary Ann Gray | KROS | Stock Option (right to buy) | Award | 10,500 | 10,500 | 04 Jun 2025 | Direct | |||
| Jean Jacques Bienaime | KROS | Common Stock | Award | 2625% | 5,250 | 5,450 | 04 Jun 2025 | Direct | ||
| Jean Jacques Bienaime | KROS | Stock Option (right to buy) | Award | 10,500 | 10,500 | 04 Jun 2025 | Direct | |||
| ADAR1 Capital Management, LLC | KROS | Put Option (obligation to buy) | Expiration of short derivative position | -100% | -178 | 0 | 16 May 2025 | By Spearhead Insurance Solutions IDF, LLC | ||
| ADAR1 Capital Management, LLC | KROS | Put Option (obligation to buy) | Expiration of short derivative position | -100% | -1,136 | 0 | 16 May 2025 | By ADAR1 Partners, LP | ||
| ADAR1 Capital Management, LLC | KROS | Common Stock | Purchase | 2.25% | $153,752 | $9.40 | 16,365 | 743,558 | 09 Apr 2025 | By Spearhead Insurance Solutions IDF, LLC |
| ADAR1 Capital Management, LLC | KROS | Common Stock | Purchase | 26.4% | $9,310,760 | $10.14 | 917,893 | 4,392,737 | 09 Apr 2025 | By ADAR1 Partners, LP |
| ADAR1 Capital Management, LLC | KROS | Cash-Settled Total Return Swaps | Other | -94.7% | -899,333 | 50,000 | 09 Apr 2025 | By ADAR1 Partners, LP |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.